Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H15N2O3.Na |
Molecular Weight | 246.2382 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(C)CC1(CC=C)C(=O)NC(=O)[N-]C1=O
InChI
InChIKey=LIZXGILRVOONMO-UHFFFAOYSA-M
InChI=1S/C11H16N2O3.Na/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15;/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16);/q;+1/p-1
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H16N2O3 |
Molecular Weight | 224.2563 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Butalbital, 5-allyl-5-isobutylbarbituric acid, is a barbiturate with an intermediate duration of action. The different combinations with butalbital is approved. One of them is fioricet with codeine (butalbital, ccetaminophen, caffeine, and codeine phosphate) which is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of fioricet with codeine in the treatment of multiple recurrent headaches is unavailable. Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. This compound in general may appear in breast milk and readily cross the placental barrier. Monoamine oxidase (MAO) inhibitors may enhance the CNS effects. The mechanism of action for butalbital is proposed the following: this compound binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11606331 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | FIORICET W/ CODEINE Approved UseFioricet with Codeine is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Fioricet with Codeine in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. Launch Date7.1245437E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1 μg/mL |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
BUTALBITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29124988/ |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
BUTALBITAL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35 h |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
BUTALBITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
55% |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: ACETAMINOPHEN |
BUTALBITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg single, oral Recommended Dose: 100 mg Route: oral Route: single Dose: 100 mg Co-administed with:: acetylsalicylic acid(660 mg oral) Sources: caffeine(80 mg oral) |
healthy, 27-41 n = 5 Health Status: healthy Age Group: 27-41 Population Size: 5 Sources: |
|
2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Co-administed with:: acetylsalicylic acid(13000 mg oral; single) Sources: Page: p.1,2caffeine(1600 mg oral; single) codeine(1200 mg oral; single) |
unhealthy, 67 n = 1 Health Status: unhealthy Condition: Headache Age Group: 67 Sex: F Population Size: 1 Sources: Page: p.1,2 |
Other AEs: Coma... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Coma | 2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Co-administed with:: acetylsalicylic acid(13000 mg oral; single) Sources: Page: p.1,2caffeine(1600 mg oral; single) codeine(1200 mg oral; single) |
unhealthy, 67 n = 1 Health Status: unhealthy Condition: Headache Age Group: 67 Sex: F Population Size: 1 Sources: Page: p.1,2 |
PubMed
Title | Date | PubMed |
---|---|---|
Do butalbital-containing products have a role in the management of migraine? | 2002 Aug |
|
Health resource utilization of the emergency department headache "repeater". | 2002 Sep |
|
Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. | 2005 Sep |
|
Determinants of migraine emergency department utilization in the georgia medicaid population. | 2007 Oct |
|
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. | 2009 Apr 28 |
|
Breaking the cycle of medication overuse headache. | 2010 Apr |
|
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. | 2010 Feb 18 |
|
Why do migraineurs abuse butalbital-containing combination analgesics? | 2010 Jul |
|
Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. | 2010 Jul 1 |
Sample Use Guides
Fioricet with Codeine (Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate): One or 2 capsules every 4 hours. Total daily dosage should not exceed 6 capsules. Extended and repeated use of this product is not recommended because of the potential for physical dependence.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:52:24 UTC 2023
by
admin
on
Fri Dec 15 15:52:24 UTC 2023
|
Record UNII |
BBH31P2ABJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2100
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
245-732-3
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
23554-70-3
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
SUB00910MIG
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
100000084857
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
DBSALT002235
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
DTXSID40946317
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
BBH31P2ABJ
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY | |||
|
14148200
Created by
admin on Fri Dec 15 15:52:24 UTC 2023 , Edited by admin on Fri Dec 15 15:52:24 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |